36 Results for "

metastases

" in MedChemExpress (MCE) Product Catalog:
Products (36)

36 Results for "metastases" in MCE Product Catalog:

13
13 Publications Verification
Cat. No.: HY-109566
CAS No.: 2089288-03-7
Purity:  99.22%
Synonyms: AZD1390
Research Areas:  

Cancer

Elrelesertib (AZD1390) is an orally active, brain-penetrant ATM kinase inhibitor with IC50 values of 0.78 nM. Elrelesertib blocks ATM-dependent DNA damage response, inhibits ATM autophosphorylation and downstream Chk2, Rad50 phosphorylation, and accumulates at DNA breaks. Elrelesertib acts as a radiosensitizer, induces apoptosis, genomic instability, G2-M cell cycle arrest, ROS elevation, and mitochondrial membrane potential alteration. Elrelesertib has low efflux liability against P-gp and BCRP. Elrelesertib can be used for the research of central nervous system malignancies, glioblastoma multiforme, glioma, lung cancer brain metastases, and breast cancer .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-13535A
CAS No.: 904763-27-5
Purity:  99.04%
Synonyms: ATN-161 TFA salt
Target:  

Integrin

Research Areas:  

Cancer

ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-A0037
CAS No.: 180916-16-9
Synonyms: CP-336156
Target:  

Estrogen Receptor/ERR

Research Areas:  

Inflammation/Immunology Cancer

Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM). Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-A0038
CAS No.: 190791-29-8
Synonyms: CP-336156 tartrate
Target:  

Estrogen Receptor/ERR

Research Areas:  

Endocrinology Cancer

Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM) . Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P99667
CAS No.: 1391727-24-4
Synonyms: OMP-54F28; FZD8-Fc

Target:  

Wnt

Research Areas:  

Cancer

Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P5126
CAS No.: 1192362-32-5
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P5126A
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-103316A
CAS No.: 874374-25-1
Purity:  99.92%
Target:  

Calcium Channel

Research Areas:  

Cardiovascular Disease Cancer

Ned 19 is a selective membrane-permeant non competitive NAADP antagonist and inhibits NAADP-mediated Ca 2+ signaling, with an IC50 of 65 nM . Ned 19 strongly inhibits tumor growth and vascularization as well as lung metastases in mice .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-33299
CAS No.: 154235-77-5
Synonyms: BTCA
Research Areas:  

Cancer

Serpin B9-IN-1 (BTCA) is an inhibitor that specifically targets Serpin B9 (SB9); SB9 is a natural inhibitor of granzyme B (GrB) , but may promote the metastasis of lung cancer cells into the bone marrow. SB9-overexpressing cancer cells promote proliferation and metastasis in an immune cell-dependent manner by binding to GrB. Inhibition of SB9 by Serpin B9-IN-1 significantly inhibits immunotherapy of lung cancer bone metastases in the caudal artery (CA) mouse model (LCBM) .
loading...
    loading...
Cat. No.: HY-159480
CAS No.: 2907782-78-7
Target:  

Src ATM/ATR Apoptosis mTOR AMPK

Research Areas:  

Cancer

AD1058 is an orally active, selective, and BBB-permeable inhibitor of ATR (IC50: 1.6 nM). AD1058 exhibits anticancer activity by inhibiting tumor cell proliferation, inducing cell cycle arrest, and promoting apoptosis. AD1058 is suitable for research on advanced malignancies and brain metastases .
loading...
    loading...
Cat. No.: HY-153450
CAS No.: 2308504-22-3
Purity:  99.75%
Research Areas:  

Cancer

JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-159500
CAS No.: 2206660-94-6
Synonyms: OTL-0078; OTL78
Target:  

PSMA

Research Areas:  

Cancer

Zopocianine (OTL-0078; OTL78) is a near-infrared optical probe targeting PSMA. Zopocianine binds to PSMA on the surface of PSMA-expressing cells, enters cells via receptor-mediated endocytosis, and accumulates in acidic endosomes. Zopocianine selectively accumulates in PSMA-positive cancer tissues and enables the detection of small tumors, primary prostate tumors, and locoregional metastases. Zopocianine helps achieve negative tumor surgical margins during fluorescence-guided surgery. Zopocianine is applicable to research related to prostate cancer .
loading...
    loading...
Cat. No.: HY-111083
CAS No.: 931695-79-3
Purity:  99.65%
Synonyms: CID23612552
Target:  

GPR55 PERK PKC ERK p38 MAPK

Research Areas:  

Metabolic Disease Cancer

ML191 (CID23612552) is a GPR55 antagonist. ML191 inhibits ERK phosphorylation and PKC β II translocation downstream of GPR55 signaling. ML191 suppresses LPI-induced activation of ERK1/2 and p38 MAPK signaling, blocks the transcription of RANKL-induced osteoclastogenesis markers, and reduces the bone resorption activity of mature osteoclasts promoted by RANKL. ML191 can be used to investigate diseases associated with bone degradation caused by excessive osteoclast activation, such as osteoporosis and bone damage during the formation stage of bone metastases .
loading...
    loading...
Cat. No.: HY-19376
CAS No.: 201653-76-1
Target:  

FAK

Research Areas:  

Cancer

NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration.
loading...
    loading...
Cat. No.: HY-139564
CAS No.: 1908409-18-6
Research Areas:  

Cancer

DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases .
loading...
    loading...
Cat. No.: HY-176869
CAS No.: 1431625-66-9
Target:  

Drug Derivative

Research Areas:  

Cancer

EMC-AANL-DOX is a legumain-activated prodrug conjugate of Doxorubicin (DOX) (HY-15142A). EMC-AANL-DOX shows antitumor activity in mouse models of neuroblastoma (NB), breast cancer (4T1), fibrosarcoma (HT1080), and colorectal cancer liver metastases (CT26). EMC-AANL-DOX can be used for cancer research .
loading...
    loading...
Cat. No.: HY-P10012
CAS No.: 148805-91-8
Synonyms: GYK-DTPA
Pendetide is a chelating agent, can be conjugated with Indium (111In) Capromab for further diagnostic use. Capromab pendetide is a FDA-approved imaging agent for the detection of soft tissue metastases in prostate carcinoma . Pendetide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
loading...
    loading...
Cat. No.: HY-P1816
CAS No.: 136466-51-8
Target:  

Integrin

Research Areas:  

Cancer

The connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. Fibronectin CS1 Peptide lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastasis models .
loading...
    loading...
Cat. No.: HY-164401
CAS No.: 1802735-28-9
Research Areas:  

Cancer

QBS10072S is a LAT1-selective substrate with blood-brain barrier permeability that inhibits tumor growth. QBS10072S enters LAT1-expressing tumor cells via LAT1-mediated active transport, induces interstrand DNA cross-linking and cell apoptosis, and reduces leptomeningeal dissemination. QBS10072S can be used in studies related to glioblastoma multiforme, diffuse intrinsic pontine glioma, triple-negative breast cancer brain metastases, and aggressive T-cell lymphoma .
loading...
    loading...
Cat. No.: HY-178939
Target:  

EGFR Akt PERK Apoptosis

Research Areas:  

Neurological Disease Cancer

EGFR-IN-181 is an orally active, potent, brain-penetrant EGFRL858R/T790M/C797S triple mutations inhibitor (IC50 = 1.32 nM). EGFR-IN-181 can inhibit EGFR phosphorylation (p-EGFR) and phosphorylation of its downstream signaling proteins AKT (p-AKT) and ERK (p-ERK). EGFR-IN-181 can induce apoptosis and cause G2 phase arrest. EGFR-IN-181 can be used for the study of non-small cell lung cancer (NSCLC) and brain metastases .
loading...
    loading...